| Safety experience with caspofungin in pediatric patients. | |
| | |
MedLine Citation:
|
PMID: 19779392 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population. |
| | |
Authors:
|
Theoklis Zaoutis; Thomas Lehrnbecher; Andreas H Groll; William J Steinbach; Hasan S Jafri; Johan Maertens; Angela L Ngai; Joseph W Chow; Arlene F Taylor; Kim M Strohmaier; Michael Bourque; Susan K Bradshaw; Maria Petrecz; Nicholas A Kartsonis |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Pediatric infectious disease journal Volume: 28 ISSN: 1532-0987 ISO Abbreviation: Pediatr. Infect. Dis. J. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8701858 Medline TA: Pediatr Infect Dis J Country: United States |
Other Details:
|
Languages: eng Pagination: 1132-5 Citation Subset: IM |
Affiliation:
|
Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. zaoutis@email.chop.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Congenital Transmission of Human Immunodeficiency Virus, Cytomegalovirus, and Toxoplasmosis in a Pre...
Next Document: Laryngeal Involvement in Two Severe Cases of Childhood Tuberculosis.